review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1111/J.1365-2893.1996.TB00055.X |
P698 | PubMed publication ID | 8914009 |
P2093 | author name string | Almasio P | |
Craxì A | |||
Schalm S | |||
P2860 | cites work | Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha | Q27473012 |
Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C | Q43038335 | ||
Prediction of response to interferon treatment of chronic hepatitis C. | Q43041709 | ||
Hepatitis C serotype and response to interferon therapy. | Q43048820 | ||
Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection | Q43049113 | ||
Reliability of polymerase chain reaction for detection of hepatitis C virus | Q43049524 | ||
Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment | Q44203363 | ||
Interferon and hepatitis C. | Q49203187 | ||
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C | Q58622903 | ||
Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response, | Q58803515 | ||
P433 | issue | 5 | |
P304 | page(s) | 273-276 | |
P577 | publication date | 1996-09-01 | |
P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
P1476 | title | Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria | |
P478 | volume | 3 |
Q33809532 | Definition of response to antiviral therapy in chronic hepatitis C. |
Q43674745 | Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study |
Q33940500 | Methodological issues in papers on IFN therapy: time for reappraisal. |
Q33809555 | New treatment strategies in non-responder patients with chronic hepatitis C. |
Search more.